by Janncike Kristoffersen | Jan 16, 2023
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by Else Marit Inderberg and Sébastien Wälchli’s research group at the Radium Hospital, Oslo University Hospital. ‘Clinical...
by Elisabeth Kirkeng Andersen | Jan 26, 2022
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by Else Marit Inderberg and Sébastien Wälchli’s research group at the Radium Hospital, Oslo University Hospital. ‘Clinical...
by Elisabeth Kirkeng Andersen | Nov 15, 2021
Inven2 has long experience of licence agreements, particularly in life sciences, which dominate the portfolio. The available licences are presented at all times on our website under ‘Licensing opportunities’. Contact one of our business developers for up-to-date...
by Elisabeth Kirkeng Andersen | Oct 15, 2020
Most protein-based therapeutics must be injected to be effective. That is both stressful for the patient and costly for the healthcare system. Researchers at the University of Oslo and Oslo University Hospital have recently published an article in the highly reputed...
by Elisabeth Kirkeng Andersen | Sep 25, 2020
Inven2 handles agreements for clinical studies on behalf of the Cancer Clinic at Oslo University Hospital for most Norwegian companies that develop cancer treatments. “This is an important contribution to the Norwegian health industry and shows that we are competing...
by Elisabeth Kirkeng Andersen | Aug 19, 2020
Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on a new form of cancer immunotherapy. Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at Oslo University Hospital, the...
